Similar articles

• Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

  McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. McClung MR, et al. Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f. Menopause. 2006. PMID: 16735934 Clinical Trial.
• Lasofoxifene for postmenopausal women with osteoporosis.

  Malozowski S. Malozowski S. N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454. N Engl J Med. 2010. PMID: 20558377 No abstract available.
• Another selective estrogen-receptor modulator for osteoporosis.

  Becker C. Becker C. N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847. N Engl J Med. 2010. PMID: 20181977 No abstract available.
• [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].

  Iwamoto J. Iwamoto J. Clin Calcium. 2010 Mar;20(3):396-407. Clin Calcium. 2010. PMID: 20190370 Review. Japanese.
• Lasofoxifene in osteoporosis and its place in therapy.

  Swan VJ, Hamilton CJ, Jamal SA. Swan VJ, et al. Adv Ther. 2010 Dec;27(12):917-32. doi: 10.1007/s12325-010-0081-y. Epub 2010 Nov 10. Adv Ther. 2010. PMID: 21080249 Review.